Figure 2.
No evidence for an altered peptidome by DNCB modification of HLA molecules: A, C, E, G, HLA molecule 9-mer binding motifs ±DNCB treatment (Bassani-Sternberg and Gfeller, 2016; Gfeller et al., 2018; Jessen, 2018). B, D, F, H, HLA bound peptide length distributions ±DNCB treatment (Bassani-Sternberg and Gfeller, 2016; Gfeller et al., 2018).